Le Lézard
Classified in: Health, Science and technology
Subject: AWD

Resolution Development Services Supports Children's Charity Through End of Year Promotion



WOBURN, Mass., Dec. 7, 2017 /PRNewswire/ -- During this season of giving, Resolution Development Services Inc., a leading provider of product development services to the medical, life science and consumer markets, today announced an end of the year promotion that awards one individual a new iPad and more importantly, supports Boston Children's Hospital.

Participating in the program is simple. Individuals that download Resolution Development Services' whitepaper, "Bridging the Chasm: How Product Development Services Connects Design and Manufacturing" featured on the Resolution Development Services Website will be entered into a drawing for a new iPad. The whitepaper illustrates the differences between product design and manufacturing and the critical role product development plays connecting the two disciplines to create high-quality products.

To support Boston Children's Hospital, for every person that downloads the whitepaper, $1.00 will be donated to support children's health services. A comprehensive center for pediatric health care and one of the largest pediatric medical centers in the United States, Boston Children's offers a complete range of healthcare services for children.

"As the founder and CEO of Resolution Development Services (RDS), I am committed to supporting worthy causes. We work closely with companies that provide life-saving pharmaceuticals, medical devices, and diagnostics and understand the importance of supporting these endeavors," said Leo Carayannopoulos, CEO of Resolution. "We created this end of year program as a fun way to engage our community and give to a worthy cause. Even if you have an iPad, download the whitepaper to support continuing care for children."

The promotion ends on Dec. 31, with the winner notified on Wednesday, Jan. 3.

To participate, visit www.resolutiondev.com and select the whitepaper download.

About Resolution Development Services:

With offices just outside of Boston, Resolution Development Services provides best in class hardware, software, mechanical, machine vision, and systems engineering outsourced services to clients in the United States, Canada, and Asia. Our regulatory compliant quality system makes Resolution the best choice for complex development programs.

To learn more about Resolution Development Services offerings, our charitable giving, and other partnerships, visit www.resolutiondev.com.

Contact:

Leo Carayannopoulos
leo@resolutiondev.com

 

SOURCE Resolution Development Services


These press releases may also interest you

at 19:55
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Harbour BioMed, a global biopharmaceutical company developing...

at 18:53
In response to market rumours, Capio confirms ongoing discussions relating to possible divestments of its non-Nordic operations. Capio continuously evaluates different alternatives to drive growth and create shareholder value. As part of assessing...

at 17:00
Open Access publishing is gaining popularity as the world is increasingly connected online today, facilitating archiving, indexing, data mining, retrieving, and speedy distribution of researched information. Open access publishing is producing a...

at 17:00
Renovatm Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that an abstract of a study in a preclinical model of type 1 diabetes was accepted as a...

at 16:00
People with type 1 diabetes (T1D) who take 200 mg or 400 mg of sotagliflozin in addition to optimized insulin therapy have statistically lower HbA1c levels and weight, as well as low incidence of severe hypoglycemia after a year of treatment,...

at 16:00
ORLANDO, Fla., June 24, 2018 /PRNewswire-USNewswire/ -- Adding the selective SGLT2 inhibitor dapagliflozin to intensive insulin therapy in adults with type 1 diabetes (T1D) who had sub-optimal glycemic control reduced blood glucose levels, aided in...




News published on 7 december 2017 at 17:16 and distributed by: